Evidence map›Paper›PMID 41904590›Full record

ArticleJournal of nanobiotechnology2026

Circulating miR-378a-3p attenuates pulmonary inflammation and fibrosis via BAT-lung crosstalk.

Rui He, Xuemin Peng, Ruping Pan, Qianqian Kang, Shulin Liu, Min Yang, Zhihan Wang, Hongyan Deng, Danpei Li, Yuyu Xie and 8 more

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rui He *Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Xuemin Peng *Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Ruping Pan *Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qianqian Kang *Laboratory of Endocrinology and Metabolism, Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Shulin LiuDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Min YangDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Zhihan WangDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Hongyan DengDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Danpei LiDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Yuyu XieDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Wenshe WangDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Zengzhe ZhuDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Jiadai LiuDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Jing GeDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Yulian LiuDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Ronghui GaoDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Yan YangDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China.
Yong ChenDivision of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Jiefang Road 1095, Wuhan, 430030, Hubei Province, China. tj.y.chen@vip.163.com.

Funding

National Key R&D Program of China 2022YFA0806100National Natural Science Foundation of China 82270910, 82570997, 82350610277, 82070859
6 · The paper itself

Abstract

Pulmonary fibrosis (PF) arises from persistent fibroblast activation and inflammation. Although microRNAs (miRNAs) are promising antifibrotic agents, the contribution of adipose-derived circulating miRNAs to PF remains unclear. Here, we identify brown adipose tissue (BAT) as a major source of exosomal miR-378a-3p that counteracts bleomycin (BLM)-induced PF. In fibrotic mice, BAT activity and circulating exosomal miR-378a-3p were reduced. Activating BAT by cold exposure or β3-adrenergic stimulation increased circulating and pulmonary miR-378a-3p and attenuated collagen deposition and inflammatory infiltration. Adipocyte-specific deletion of miR-378a-3p exacerbated lung inflammation and fibrosis, whereas lung-targeted overexpression of miR-378a-3p or intravenous delivery of BAT-derived exosomes enriched for miR-378a-3p ameliorated disease. Inhibition of exosome release from BAT lowered circulating miR-378a-3p and blunted the anti-fibrotic benefits of BAT activation, supporting a BAT-to-lung transfer mechanism. Mechanistically, miR-378a-3p targets Itga5 to suppress FAK-PI3K-AKT signaling and limiting fibroblast activation, while simultaneously suppressing macrophage inflammatory responses by targeting Fstl1 and suppressing NF-κB activation. Collectively, these findings identify miR-378a-3p as a BAT-derived signaling molecule with dual anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis, expanding the pathophysiological scope of BAT-mediated inter-organ communication to lung disease.

Indexed as

Adipose Tissue, BrownLungMicroRNAsPneumoniaPulmonary FibrosisAnimalsBleomycinExosomesMaleMiceMice, Inbred C57BLSignal TransductionBleomycinMicroRNAsMIRN378 microRNA, mousebrown adipose tissueexosomeinflammationlung fibrosismiR-378a-3p

Identifiers

PMID41904590
PMCPMC13151345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.